Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yuxin, Zhao Yang, Yang Aocai, Wang Yan, Xin Jiaxiang, Chen Yufan, Xing Xuewen, Liu Fei, Zou Yao, Zhao Wei, Song Lin, Gong Tao, Wang Guangbin
Аннотация
INTRODUCTION: Lecanemab provides clinical benefits in early Alzheimer's disease (AD), but its longitudinal effects on brain structure, particularly cerebrospinal fluid (CSF) compartments, remain unclear. This study examined treatment-associated structural changes using longitudinal MRI.
METHODS: Thirty-one patients with mild cognitive impairment (MCI) or early AD underwent baseline and follow-up (1-7 months) 3D T1-weighted MRI during lecanemab treatment. Gray matter (GM), ventricular, choroid plexus (CP), and perivascular space (PVS) volumes were quantified. Longitudinal changes were analyzed with paired tests and linear mixed-effects models (LMMs).
RESULTS: Significant GM volume reductions were observed in AD-vulnerable regions (hippocampus, entorhinal cortex, precuneus), with increased CSF volumes. PVS volume showed a modest, non-significant decline. CP enlargement was associated with ventricular expansion.
DISCUSSION: Lecanemab treatment was associated with coordinated parenchymal and CSF-related structural changes. CP and PVS dynamics may represent potential MRI-based markers for monitoring early AD.
METHODS: Thirty-one patients with mild cognitive impairment (MCI) or early AD underwent baseline and follow-up (1-7 months) 3D T1-weighted MRI during lecanemab treatment. Gray matter (GM), ventricular, choroid plexus (CP), and perivascular space (PVS) volumes were quantified. Longitudinal changes were analyzed with paired tests and linear mixed-effects models (LMMs).
RESULTS: Significant GM volume reductions were observed in AD-vulnerable regions (hippocampus, entorhinal cortex, precuneus), with increased CSF volumes. PVS volume showed a modest, non-significant decline. CP enlargement was associated with ventricular expansion.
DISCUSSION: Lecanemab treatment was associated with coordinated parenchymal and CSF-related structural changes. CP and PVS dynamics may represent potential MRI-based markers for monitoring early AD.